|1.||Song, Jun-Gol: 2 articles (12/2014 - 08/2013)|
|2.||Brichant, J F: 2 articles (11/2010 - 01/2000)|
|3.||Pühringer, F: 2 articles (01/2007 - 09/2001)|
|4.||Baraka, Anis: 2 articles (06/2006 - 06/2003)|
|5.||Fodale, V: 2 articles (01/2005 - 02/2004)|
|6.||Lucanto, T: 2 articles (01/2005 - 02/2004)|
|7.||Praticò, C: 2 articles (01/2005 - 02/2004)|
|8.||Santamaria, L B: 2 articles (01/2005 - 02/2004)|
|9.||Zhang, Haibo: 1 article (01/2016)|
|10.||Ghazarian, Mirna: 1 article (01/2016)|
12/01/1999 - "Although fasciculations occurred less frequently in the cisatracurium group than in the placebo group (59% vs. 85%, respectively), this difference did not reach statistical significance. "
09/01/2002 - "Cisatracurium is only effective in preventing succinylcholine-induced fasciculations when a longer pretreatment interval, i.e. "
09/01/2002 - "3 and 6 min, on the efficacy of 0.01 mg/kg cisatracurium in preventing succinylcholine-induced fasciculations and myalgia. "
02/01/2003 - "A Kruskal-Wallis analysis of variance, used to analyze data collected from the fasciculation scale, demonstrated there was no statistically significant difference in efficacy between tubocurarine and rocuronium for defasciculation or between cisatracurium and saline for defasciculation. "
12/01/1999 - "Fasciculations were observed less frequently (p < 0.05) in the d-tubocurarine and rocuronium groups compared with the placebo and cisatracurium groups. "
|2.||Critical Illness (Critically Ill)
04/01/2015 - "The aim of the present study was to perform the first comprehensive review to date of all literature relating to the use of cisatracurium in critically ill patients. "
12/01/2002 - "A comparison of two depths of prolonged neuromuscular blockade induced by cisatracurium in mechanically ventilated critically ill patients."
08/01/2001 - "Cisatracurium appears to be suitable when continuous muscle relaxation is required in critically ill patients."
01/01/2013 - "Short-term infusion of cisatracurium besylate reduces hospital mortality and barotrauma and does not appear to increase ICU-acquired weakness for critically ill adults with ARDS."
05/01/2012 - "To characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of cisatracurium in critically ill patients with severe sepsis. "
|3.||Renal Insufficiency (Renal Failure)
10/01/1995 - "Clearance of 51W89 was found to be reduced by 13% in renal failure. "
08/01/1998 - "The result of this clinical study suggest, that cisatracurium is a suitable choice for patients with renal failure. "
06/01/2002 - "Time to T4/T1 > 0.7 and > 0.9 was longer in the renal failure group as compared to the normal group and cisatracurium did not show cumulative effects in the renal failure group."
07/01/1999 - "There was no difference in the time to maintenance of adequate respiration, date of birth recollection, first analgesic administration, between the renal failure (4.8+/-2.5, 7.8+/-3.2, 12.3+/-5.3 min respectively) and the control group (5.2+/-2.8, 8.1+/-3.1, 12.7+/-5.5 min): nor were there any differences in the time to 25% T1 recovery, T1 recovery from 25% to 75%, or cisatracurium infusion rate between the renal failure group (32.1 +/-10.8 min, 18.2+/-5.5 min, 0.89+/-0.29 microg x kg(-1) min(-1) respectively) and the control group (35.9 (7.9 min, 18.4+/-3.8 min, 0.95+/-0.22 microg x kg(-1) x min(-1)). "
10/01/1995 - "A two-compartment model was fitted to the 51W89 plasma concentration data using the NONMEM program, to estimate pharmacokinetic variables and to determine the influence of renal failure, age, weight and sex. "
|4.||Coronary Artery Disease (Coronary Atherosclerosis)
08/01/1998 - "The purpose of the present study was to investigate the haemodynamic effects of high doses of cisatracurium in patients with coronary artery disease. "
05/01/1997 - "Cisatracurium besilate is not associated with dose-related histamine release (at bolus doses of < or = 8 x ED95) and, consistent with this, has demonstrated cardiovascular stability in both healthy patients (< or = 8 x ED95) and those with coronary artery disease (< or = 6 x ED95). "
01/01/2004 - "In spite of the more costly price, cisatracurium is beneficial in some end stage renal disease (ESRD) patients with coronary artery disease who need very stable hemodynamics."
08/01/1998 - "In patients with coronary artery disease, rapid cisatracurium (4-8 x ED95) boluses and vecuronium (6 x ED95) result in minor, clinically insignificant haemodynamic side effects."
08/01/1998 - "Comparison of the cardiovascular effects of cisatracurium and vecuronium in patients with coronary artery disease."
|5.||Adult Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
04/01/2015 - "Recent randomised clinical trials suggested that the use of cisatracurium is associated with better outcome in acute respiratory distress syndrome (ARDS). "
08/01/2001 - "The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome."
06/01/2008 - "We report three cases of tachyphylaxis to cisatracurium in a surgical intensive care unit (SICU): one in patient with acute respiratory distress syndrome (ARDS) and the other two with traumatic brain injury (TBI)."
04/15/2015 - "A case of resistance to rocuronium and cisatracurium in a patient with a spinal injury who developed acute respiratory distress syndrome (ARDS) is reported. "
04/15/2015 - "Resistance to rocuronium and cisatracurium in a patient with a spinal injury and acute respiratory distress syndrome."
|1.||Succinylcholine (Suxamethonium Chloride)
|3.||rocuronium (rocuronium bromide)
|6.||Tubocurarine (Tubocurarine Chloride)
|8.||Neuromuscular Blocking Agents
|1.||Artificial Respiration (Mechanical Ventilation)
|2.||Ambulatory Surgical Procedures (Outpatient Surgery)
|5.||Intensive Care (Surgical Intensive Care)